Study guide

20.2 Recruitment Feasibility and Evidence-Based Site Selection

ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Format, Eligibility and Registration

1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions

2 Chapter 2: CRA Responsibilities and Study Planning

2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy

3 Chapter 3: Protocols, Endpoints and Trial Design

3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs

4 Chapter 4: Bias Control, Blinding and Product Information

4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates

5 Chapter 5: Estimands and Device Instructions

5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training

6 Chapter 6: Ethical Foundations and Independent Oversight

6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review

7 Chapter 7: Ethics Communication and Informed Consent

7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates

8 Chapter 8: Recruitment, Retention and Confidentiality

8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access

9 Chapter 9: Safety Definitions and Classification

9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information

10 Chapter 10: Safety Detection, Reporting and Oversight

10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight

11 Chapter 11: Follow-Up, Adherence and Conflicts

11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments

12 Chapter 12: Development Stages and Product Management

12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response

13 Chapter 13: Accountability, Integrity and Regulatory Status

13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting

14 Chapter 14: Current GCP Principles and Delegation

14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority

15 Chapter 15: Oversight, Protocol Control and Amendments

15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution

16 Chapter 16: Implementation and Trial Responsibilities

16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles

17 Chapter 17: Quality Planning, Root Causes and CAPA

17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification

18 Chapter 18: Risk Assessment and Monitoring Methods

18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review

19 Chapter 19: Quality Metrics, Plans and Communication

19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication

20 Chapter 20: Site Qualification and Readiness

20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release

21 Chapter 21: Initiation, Equipment and Supplies

21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies

22 Chapter 22: Samples, Diagnostics and Financial Feasibility

22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility

23 Chapter 23: Interim Monitoring and Reporting

23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports

24 Chapter 24: Essential Records, Audits and Findings

24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning

25 Chapter 25: Close-Out, Retention and Destruction

25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access

26 Chapter 26: Source Records and Good Documentation

26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context

27 Chapter 27: Electronic Systems, Metadata and Queries

27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning

28 Chapter 28: Dataset Finalisation and Critical Data

28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings

20.2 Recruitment Feasibility and Evidence-Based Site Selection

Key Takeaways Explain This Topic AI

Eligibility criteria, consent rates and competing studies affect the attainable cohort.

Past findings require review of current restrictions and remediation evidence.

Site selection recommendations should distinguish facts, risks and remediable gaps.

Last updated: October 2026

Recruitment Feasibility and Evidence-Based Site Selection

Recruitment difficulty can be a cause of clinical trial delays and premature study termination. The CRA must rigorously interrogate the site's recruitment assertions:

Diagnostic Epidemiology vs. Protocol Criteria: The CRA reviews recent historical patient volumes from the site's Electronic Health Record (EHR) database. Rather than accepting broad claims like "We see 500 diabetes patients a year," the CRA applies specific protocol eligibility criteria: How many of those 500 patients have an HbA1c between 7.5% and 10.0%, are free of advanced renal impairment (eGFR ≥ 60 mL/min \ge 60\text{ mL/min} ≥ 60 mL/min ), and are not taking exclusionary medications? Often, an initial pool of 500 shrinks to 15 eligible candidates.

Historical Enrollment Metrics: The CRA verifies site performance on past comparable trials. Did the site meet its contracted enrollment targets, or did it fail to enroll or require contract amendments?

Competing Clinical Trials: The CRA must audit all active and upcoming studies at the institution. Are other investigators within the clinic or adjacent departments running studies targeting the exact same patient population? If two competing trials target third-line metastatic breast cancer, how will eligible patients be allocated between the studies?

D. Facilities, equipment and continuity

Verify facilities against the actual protocol: product storage and environmental monitoring, sample processing, imaging or other diagnostics, secure records and appropriate emergency support. Calibration, maintenance and contingency arrangements should fit the equipment and risk. Do not assume every site needs the same freezer, generator or brand of temperature logger.

Request evidence: an equipment identifier, service record, required operating range, current calibration where relevant and a workable failure response. Ask staff to describe an out-of-hours alarm or a courier cancellation. A device present in a room is not proof that trained staff, compatible supplies or backup arrangements are available. Remediable gaps should have owners and evidence of correction before the affected activity begins.

E. Institutional Review Board (IRB) / Ethics Committee Processes

Institutional ethics review workflows dictate study activation timelines:

Central IRB vs. Local Institutional IRB: Does the institution permit reliance on an independent central IRB (e.g., WCG, Advarra) via a Master Services Agreement, or does institutional policy mandate review by an internal hospital IRB?

Submission Deadlines & Meeting Calendars: Internal IRBs often meet only monthly, requiring submissions 3 to 4 weeks prior to the meeting date. If a submission window is missed, activation is delayed by 6 to 8 weeks.

Ancillary Committees: Institutional delays frequently stem from ancillary committees, such as Institutional Biosafety Committees (IBC) for gene therapies, Radiation Safety Committees (RSC), or internal Scientific Review Committees (SRC).

Evaluating significant concerns

Verify investigator qualifications and regulatory standing as applicable to the jurisdiction and protocol. ACRP's ECO includes verifying appropriate qualifications and standing, but no ICH global disqualification directory exists. Relevant restrictions, unresolved prior findings, unwillingness to provide access, inadequate oversight or resources, and unreliable recruitment evidence can affect suitability.

A previous observation or warning is not automatically proof that every future trial is prohibited. Review the actual restriction, corrective actions and current evidence with sponsor regulatory/quality functions. Conversely, a strong recruitment record cannot compensate for a legal restriction or unresolved serious risk. Document the facts and rationale, and let the authorised sponsor function make the selection decision.

Competing studies and staff turnover are feasibility risks to assess, not universal automatic exclusions. Quantify the eligible pool and capacity, establish a workable allocation/coverage plan and verify it rather than applying invented thresholds such as a maximum trial count or percentage of annual turnover.

CRA Documentation: The PSV Report and Objective Recommendation

Following the visit, the CRA synthesizes all clinical, operational, and facility data into a formal, auditable Pre-Study Visit Report .

Report Contents and Structure

The PSV report must document concrete, factual observations rather than vague impressions:

Detailed meeting minutes with the PI, Sub-investigators, lead CRC, and research pharmacist.

Specific equipment serial numbers, calibration stickers, and temperature logging curves inspected during the walk-through.

Verified historical patient recruitment rates and institutional database search results.

Comprehensive list of active competing clinical trials and the site's patient allocation strategy.

Anticipated IRB review timelines, contract negotiation terms, and budget parameters.

The Site Recommendation Framework

The CRA concludes the report with a clear, evidence-based recommendation across one of three standard categories:

Selected / Recommended: The site possesses exceptional qualifications, demonstrated patient volume, modern equipment, experienced personnel, and an engaged PI with verifiable time.

Conditionally Approved: The site demonstrates strong clinical potential but possesses minor, remediable deficiencies (e.g., the pharmacy needs to install a secondary appropriately calibrated backup data logger, or the site must identify and train a designated backup coordinator). Formal selection is withheld until written proof of remediation is verified.

Rejected / Disqualified: The site displays insurmountable operational vulnerabilities, unaddressed regulatory sanctions, inadequate patient volume, an uncooperative or overextended investigator, or severe infrastructure defects that compromise study integrity.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .